| 20.9648 -0.845 (-3.88%) | 12-08 14:43 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 27.22 |
1-year : | 31.8 |
| Resists | First : | 23.3 |
Second : | 27.22 |
| Pivot price | 21.44 |
|||
| Supports | First : | 19.28 |
Second : | 16.79 |
| MAs | MA(5) : | 21.12  |
MA(20) : | 21.13 |
| MA(100) : | 20.35 |
MA(250) : | 0 | |
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 47.7 |
D(3) : | 46.5 |
| RSI | RSI(14): 49 |
|||
| 52-week | High : | 25.37 | Low : | 13.3 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ELVN ] has closed above bottom band by 27.4%. Bollinger Bands are 33.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 21.86 - 21.94 | 21.94 - 22.01 |
| Low: | 20.76 - 20.86 | 20.86 - 20.95 |
| Close: | 21.65 - 21.79 | 21.79 - 21.92 |
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
Mon, 08 Dec 2025
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Sat, 06 Dec 2025
Affinity Asset Advisors LLC Buys Shares of 400,000 Enliven Therapeutics, Inc. $ELVN - MarketBeat
Thu, 04 Dec 2025
Enliven Therapeutics (ELVN): Assessing Valuation After a Recent 13% Share Price Rebound - simplywall.st
Wed, 03 Dec 2025
Wall Street Analysts Believe Enliven Therapeutics, Inc. (ELVN) Could Rally 101.26%: Here's is How to Trade - Zacks Investment Research
Tue, 02 Dec 2025
Enliven Therapeutics (NASDAQ:ELVN) Shares Down 8% - Time to Sell? - MarketBeat
Mon, 01 Dec 2025
Geode Capital Management LLC Grows Position in Enliven Therapeutics, Inc. $ELVN - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 59 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 8.2 (%) |
| Held by Institutions | 104.7 (%) |
| Shares Short | 7,790 (K) |
| Shares Short P.Month | 6,420 (K) |
| EPS | -1.81 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.02 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -17.7 % |
| Return on Equity (ttm) | -25.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.89 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -72 (M) |
| Levered Free Cash Flow | -46 (M) |
| PE Ratio | -11.53 |
| PEG Ratio | 0 |
| Price to Book value | 2.59 |
| Price to Sales | 0 |
| Price to Cash Flow | -17.28 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|